Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MASH (Metabolic Liver Disease) Combination Therapy Market: THR-Beta Agonist and GLP-1 Combination Demand, Resmetirom Commercial Foundation Growth, and siRNA-Small-Molecule Pairing Adoption to Drive Strong Market Expansion Through 2035

The global MASH (Metabolic Liver Disease) Combination Therapy Market is projected to expand at a strong CAGR of 31.3% through 2035, driven by sustained demand for thyroid hormone receptor-beta agonist and GLP-1 receptor agonist combination regimens, growing commercial foundation established by resmetirom’s blockbuster-trajectory sales performance, and continued advancement of siRNA and small-molecule combination pairings. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises resmetirom (Rezdiffra) as the established commercial and combination-therapy foundation, with Madrigal Pharmaceuticals’ pipeline explicitly incorporating PNPLA3-targeted siRNA plus oral THR-beta agonist and multiple siRNA-resmetirom combination programs.

The market’s strong 31.3% CAGR reflects a rapidly expanding commercial foundation and disease burden: resmetirom achieved USD 958.4 million in 2025 sales, just shy of the unofficial USD 1 billion blockbuster threshold, while metabolic dysfunction-associated steatotic liver disease affects an estimated 30% of the global adult population, with U.S. MASH cases projected to grow from 14.9 million in 2020 to 23.2 million by 2050. Building on resmetirom’s foundational approval as monotherapy for non-cirrhotic MASH with F2-F3 fibrosis, biopharmaceutical developers increasingly pursue combination regimens pairing liver-directed thyroid hormone receptor-beta agonism with metabolic mechanisms including GLP-1, GLP-1/GIP, and GLP-1/glucagon receptor agonism, alongside emerging siRNA-based approaches targeting genetic risk factors such as PNPLA3. Coverage extending across multiple combination types, primary combination partners, and mechanisms underscores the breadth of clinical infrastructure now supporting this rapidly expanding combination therapy category.

Executive Snapshot

How does THR-beta agonist and GLP-1 combination demand drive the MASH combination therapy market?
Hepatology and endocrinology treatment centers continue to evaluate combination regimens pairing resmetirom’s liver-directed thyroid hormone receptor-beta agonism with GLP-1, GLP-1/GIP, and GLP-1/glucagon receptor agonist mechanisms, establishing this combination category as the primary strategic direction for the field given the complementary liver-directed and systemic metabolic mechanisms involved. As combination clinical evidence continues to accumulate, procurement associated with THR-beta and incretin combination therapy is expected to remain the dominant category through the forecast period.

What role does resmetirom’s commercial foundation growth play in market expansion?
Treatment centers continue to build combination treatment protocols around resmetirom, which achieved USD 958.4 million in 2025 sales as the first FDA-approved MASH therapy, sustaining structured demand from developers pursuing combination partnerships that leverage this established commercial and clinical foundation.

How does siRNA and small-molecule combination pairing adoption sustain market growth?
Biopharmaceutical developers, led by Madrigal Pharmaceuticals’ pipeline incorporating PNPLA3-targeted siRNA alongside its oral THR-beta agonist, continue to advance genetic-risk-factor-targeted combination approaches, sustaining structured demand from developers pursuing this differentiated mechanism pairing relative to purely small-molecule or purely biologic combination strategies.

What is driving demand for MASH combination therapy amid the disease’s substantial and growing prevalence?
Developers continue to size their combination therapy commercial opportunity against a global MASLD population affecting approximately 30% of adults worldwide, with U.S. MASH cases projected to grow from 14.9 million in 2020 to 23.2 million by 2050, generating sustained interest among biopharmaceutical developers and hepatology treatment centers pursuing this expanding addressable population.

How does anti-fibrotic and anti-inflammatory combination demand sustain the market?
Biopharmaceutical developers continue to pair liver-directed and metabolic mechanisms with anti-fibrotic and anti-inflammatory combination partners, sustaining structured demand from developers pursuing comprehensive disease modification addressing both the metabolic drivers and the fibrotic consequences of MASH.

Which MASH combination therapy market segments are growing fastest?
The fastest-growing segments include THR-beta agonist plus GLP-1/GIP or GLP-1/glucagon triple-mechanism combinations, siRNA plus small-molecule pairings, fixed-dose combination formulations, and combination regimens targeting patients with advanced fibrosis.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: MASH (Metabolic Liver Disease) Combination Therapy Market

  • Clinical and commercial data snapshot sustaining the evidentiary foundation for the category’s growth outlook: Resmetirom achieved USD 958.4 million in 2025 sales approaching blockbuster status; global MASLD prevalence affects approximately 30% of adults worldwide; and U.S. MASH cases are projected to grow from 14.9 million in 2020 to 23.2 million by 2050.
  • THR-beta agonist plus GLP-1 receptor agonist combinations sustaining the leading share of current combination development activity: This pairing continues to represent the most clinically advanced and commercially anticipated combination strategy within the current MASH pipeline.
  • Resmetirom sustaining the foundational commercial anchor around which combination therapy strategies continue to be built: This established monotherapy continues to anchor the broader combination therapy category’s commercial and clinical development strategy.
  • siRNA plus small-molecule combinations sustaining structured demand growth as a differentiated genetic-risk-factor-targeted approach: PNPLA3-targeted programs continue to represent an important area of pipeline innovation given this gene’s established role in MASH genetic risk.
  • Non-cirrhotic MASH with moderate-to-advanced fibrosis sustaining the primary current treatment population: This established regulatory and clinical population continues to anchor combination therapy development strategy across the category.
  • Fixed-dose and free combination formulations sustaining parallel development pathways across the category: Both formulation approaches continue to represent viable commercial strategies as combination regimens advance through clinical development.

Market Segmentation: MASH (Metabolic Liver Disease) Combination Therapy Market

By Combination Type
  • Liver-Directed + Metabolic Therapy
  • Liver-Directed + Anti-Fibrotic Therapy
  • Metabolic + Anti-Fibrotic Therapy
  • Metabolic + Anti-Inflammatory Therapy
  • Anti-Fibrotic + Anti-Inflammatory Therapy
  • Dual Metabolic Therapy
  • Dual Liver-Directed Therapy
  • Triple-Mechanism Combination
  • Multi-Drug Combination
  • Fixed-Dose Combination
  • Free Combination / Co-Administration
By Mechanism of Action
  • Metabolic Mechanisms
  • Liver-Directed Mechanisms
  • Fibrosis / Inflammation
  • Others
By Therapeutic Component
  • Resmetirom
  • Semaglutide
  • Tirzepatide
  • Survodutide
  • Efruxifermin
  • Lanifibranor
  • Denifanstat
  • Ervogastat
  • VK2809
  • PNPLA3-Targeted siRNA
  • Others
By Dosing Frequency
  • Once Daily
  • Twice Daily
  • Once Weekly
  • Every 2 Weeks
  • Monthly
  • Extended-Interval
  • Sequential / Induction-Maintenance
By Disease Stage
  • MASH Without Significant Fibrosis
  • F1 Fibrosis
  • F2 Fibrosis
  • F3 Fibrosis
  • Compensated F4 / MASH Cirrhosis
  • Advanced Fibrosis
  • Non-Cirrhotic MASH
  • Cirrhotic MASH
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Hospitals
  • Specialty Clinics
  • Gastroenterology Practices
  • Hepatology Centers
  • Endocrinology Practices
  • Obesity Treatment Centers
  • Academic Medical Centers
  • Specialty Pharmacies
  • Retail Pharmacies
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: MASH (Metabolic Liver Disease) Combination Therapy Market

  1. Sustained resmetirom commercial performance driving continued combination therapy pipeline investment: Approaching blockbuster sales continue to support structured demand above the discretionary specialty pharmaceutical baseline.
  2. Growing global MASLD and MASH prevalence supporting a structurally expanding addressable combination therapy population: Projected growth from 14.9 million to 23.2 million U.S. MASH cases by 2050 continues to broaden the category’s long-term commercial opportunity.
  3. Continued biopharmaceutical investment in complementary mechanism pairing supporting THR-beta and incretin combination development: This combination strategy continues to attract structured developer investment pursuing enhanced efficacy relative to monotherapy approaches.
  4. Sustained interest in genetic-risk-factor-targeted approaches supporting siRNA and small-molecule combination pairing: PNPLA3-targeted programs continue to generate incremental developer interest in this differentiated combination strategy.
  5. Growing clinical focus on comprehensive disease modification supporting anti-fibrotic and anti-inflammatory combination development: These combination approaches continue to attract structured investment pursuing treatment beyond metabolic risk factor modification alone.
  6. Maturing Phase II and Phase III combination pipeline supporting an approaching wave of regulatory submissions: A growing number of combination candidates continues to focus hepatology treatment center and payer attention on the category’s next phase of expansion.

Regional Outlook: MASH (Metabolic Liver Disease) Combination Therapy Market

  • North America: The United States accounts for the largest share of regional demand, supported by resmetirom’s established commercial presence and extensive hepatology and endocrinology treatment center infrastructure; regional treatment centers continue to expand combination therapy protocol development.
  • Europe: Germany, France, and the United Kingdom anchor regional demand, supported by growing specialized liver disease center capacity and anticipated regulatory review of resmetirom and combination candidates; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: China, Japan, and India represent some of the fastest-growing regional markets given substantial and rising MASLD prevalence linked to increasing obesity and type 2 diabetes rates; regional treatment centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized hepatology centers begin to expand access to MASH combination therapy; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: MASH (Metabolic Liver Disease) Combination Therapy Market

Key Players
Madrigal Pharmaceuticals, Inc., Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Akero Therapeutics, Inc., 89bio, Inc.

  • Madrigal Pharmaceuticals, Inc. [February 2026] — confirmed 2025 sales of Rezdiffra (resmetirom) reached USD 958.4 million, with the company noting continued expansion of its combination pipeline incorporating PNPLA3-targeted siRNA alongside its approved thyroid hormone receptor-beta agonist.
  • Novo Nordisk A/S [December 2025] — reported continued Phase 3 clinical development of semaglutide combination approaches for MASH, with the company noting sustained investigator interest in pairing GLP-1 receptor agonism with liver-directed therapy.
  • Akero Therapeutics, Inc. [September 2025] — confirmed continued clinical development of its FGF21 analogue efruxifermin in combination with GLP-1 receptor agonist therapy, with the company reporting structured investor interest in this complementary mechanism pairing.

Consultant POV

The MASH (Metabolic Liver Disease) Combination Therapy Market’s strong 31.3% CAGR outlook through 2035 is anchored in sustained THR-beta agonist and GLP-1 combination demand, growing resmetirom commercial foundation activity, and continued siRNA-small-molecule pairing adoption, set against a global MASLD population affecting approximately 30% of adults. Sustained clinical and commercial investment from companies including Madrigal Pharmaceuticals, Inc., Novo Nordisk A/S, and Akero Therapeutics, Inc. confirms the MASH Combination Therapy Market will sustain strong growth through 2035.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report